+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infantile Spasms Therapeutics Market - Global Forecast 2026-2032- Product Image
Infantile Spasms Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Infantile Spasms Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 197 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904865
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The evolving infantile spasms therapeutics market is redefining standards in pediatric neurology, demanding a focused response from senior executives as clinical innovation, supply chain complexity, and the pursuit of individualized diagnostics converge.

Market Snapshot: Infantile Spasms Therapeutics Market Outlook

The infantile spasms therapeutics market is projected to expand from USD 428.78 million in 2025 to USD 453.84 million in 2026, advancing at a CAGR of 6.78% and reaching USD 679.12 million by 2032. This robust trajectory is underpinned by pressures to enhance early intervention, maintain supply chain resilience, and accelerate product advancement. Regulatory and clinical environments continue to change, influencing how companies compete and prepare for future market demands.

Scope & Segmentation

  • Therapeutic Classes: The sector covers anti-epileptic drugs such as vigabatrin, as well as hormonal therapies like adrenocorticotropic hormone and corticosteroids. Each class brings distinct requirements for monitoring, safety oversight, and administration protocols, necessitating tailored approaches to maximize patient outcomes.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, specialty distributors, and online pharmacies represent the principal avenues for providing therapies. These routes directly affect access, patient compliance, and the seamless continuation of care, emphasizing the need for distribution alignment with the needs of targeted populations.
  • Routes of Administration: Injectable and oral forms are available, chosen based on clinical requirements. Injectable options require medical supervision, while oral medications facilitate flexible dosing and easier administration for pediatric patients.
  • Diagnostic Modalities: Next-generation sequencing, metabolic profiling, and established electroencephalography techniques serve as essential tools, enabling precise cause identification and supporting more individualized care strategies.
  • Geographic Regions: Analysis spans the Americas, Europe, Middle East & Africa, and Asia-Pacific. Each area exhibits unique capabilities in diagnosis, access to therapies, and healthcare system infrastructure, shaping both challenges and market opportunities.

Key Takeaways for Decision Makers

  • Advancing diagnostic capabilities with expanded genetic platforms accelerates correct identification and supports precise, patient-centric therapeutic strategies.
  • Development of molecularly targeted and neurosteroid-based therapeutics is creating alternatives that may redefine standards of care in infantile spasms management.
  • Strengthening supply networks—particularly hospital and specialty-focused distribution—protects product availability and can improve patient treatment consistency.
  • Access and clinical capabilities remain uneven between regions, highlighting the importance of integrated care networks and cross-sector collaboration to reduce disparity.
  • Aligning incentives among manufacturers, payers, and advocacy groups supports shared goals in access, quality improvement, and enhanced patient outcomes.

Tariff Impact: Navigating Trade Disruptions

Recent U.S. tariffs have recalibrated global supply chains for the infantile spasms therapeutics market. Modifications to import policies require manufacturers to reassess sourcing strategies by advancing near-shoring, increasing inventory buffers, and diversifying distribution channels. These actions help shield against procurement delays and uphold continuity in therapy, which is particularly crucial for pediatric patients. Flexible contracting with hospitals and payers has also emerged as a risk mitigation measure to counter supply interruptions.

Methodology & Data Sources

This analysis is driven by a systematic assessment of clinical and regulatory data, amplified by targeted interviews with pediatric neurology specialists and supply chain leaders. Real-world patterns from hospital and specialty pharmacy datasets, along with ongoing trade and policy monitoring, reinforce all findings and recommendations.

Why This Report Matters

  • Provides actionable guidance for investments in diagnostics, therapeutics, and supply network strategies across the infantile spasms therapeutics market.
  • Equips executive leaders with insights on regional variances, regulatory complexities, and emerging risk factors—such as supply volatility—to support proactive and confident decision-making.
  • Aligns research and commercial priorities with clinical standards to help organizations deliver more consistent therapeutic access and improved pediatric neurological care.

Conclusion

Sustained growth in the infantile spasms therapeutics market calls for a cohesive approach blending diagnostic precision, broad treatment access, and operational flexibility. Organizations fostering collaborative, evidence-driven strategies will enhance outcomes and resilience across all care settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Infantile Spasms Therapeutics Market, by Therapeutic Class
8.1. Antiepileptic / Anticonvulsant Drugs (AEDs)
8.1.1. Vigabatrin
8.1.2. Levetiracetam
8.1.3. Topiramate
8.1.4. Zonisamide
8.1.5. Valproate
8.2. Hormonal Therapies
8.2.1. Adrenocorticotropic Hormone
8.2.2. Corticosteroids
8.3. Combination Therapies
8.3.1. ACTH + Vigabatrin
8.3.2. Steroids + AEDs
9. Infantile Spasms Therapeutics Market, by Route Of Administration
9.1. Injectable
9.1.1. Intramuscular
9.1.2. Intravenous
9.2. Oral
9.2.1. Solution
9.2.2. Tablet
10. Infantile Spasms Therapeutics Market, by Distribution Channel
10.1. Hospital Pharmacies
10.2. Online Pharmacies
10.3. Retail Pharmacies
11. Infantile Spasms Therapeutics Market, by Indication Type / Etiology
11.1. Idiopathic Infantile Spasms
11.2. Symptomatic Infantile Spasms
11.3. Cryptogenic Infantile Spasms
12. Infantile Spasms Therapeutics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Infantile Spasms Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Infantile Spasms Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Infantile Spasms Therapeutics Market
16. China Infantile Spasms Therapeutics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Amneal Pharmaceuticals LLC
17.6. BIOSPACE, INC.
17.7. CIPLA LIMITED
17.8. Eisai Co., Ltd.Marinus Pharmaceuticals, Inc.
17.9. Endo International plc
17.10. Genix Pharma
17.11. Hetero Labs Ltd.
17.12. Intas Pharmaceuticals Ltd.
17.13. Ionis Pharmaceuticals, Inc.
17.14. Mallinckrodt plc
17.15. Marinus Pharmaceuticals, Inc.
17.16. Merz Pharma GmbH & Co. KGaA
17.17. MSN Laboratories
17.18. ORPHELIA Pharma
17.19. Ovid Therapeutics, Inc.
17.20. Sanofi S.A.
17.21. SGPharma Pvt. Ltd.
17.22. Teva Pharmaceutical Industries Ltd.
17.23. UCB Pharma SA
17.24. Zydus Group
List of Figures
FIGURE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LEVETIRACETAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY LEVETIRACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ZONISAMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ZONISAMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ZONISAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VALPROATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ACTH + VIGABATRIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ACTH + VIGABATRIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ACTH + VIGABATRIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STEROIDS + AEDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STEROIDS + AEDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STEROIDS + AEDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY IDIOPATHIC INFANTILE SPASMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY IDIOPATHIC INFANTILE SPASMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY IDIOPATHIC INFANTILE SPASMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC INFANTILE SPASMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC INFANTILE SPASMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SYMPTOMATIC INFANTILE SPASMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CRYPTOGENIC INFANTILE SPASMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CRYPTOGENIC INFANTILE SPASMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CRYPTOGENIC INFANTILE SPASMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 87. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 124. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 126. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 127. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 128. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 129. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 131. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 132. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 144. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 146. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 147. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 148. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 149. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 151. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 152. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 167. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 168. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 169. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 170. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 172. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 173. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 175. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 177. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 178. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 179. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 180. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 182. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 183. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 195. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 197. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 198. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 199. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 200. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 202. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 203. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 205. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 207. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 208. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 209. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 210. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 212. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 213. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 215. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 216. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 217. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 218. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 219. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 220. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 222. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 223. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)
TABLE 236. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 238. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2018-2032 (USD MILLION)
TABLE 239. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 240. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2032 (USD MILLION)
TABLE 241. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 243. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 244. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Infantile Spasms Therapeutics market report include:
  • Amneal Pharmaceuticals LLC
  • BIOSPACE, INC.
  • CIPLA LIMITED
  • Eisai Co., Ltd.Marinus Pharmaceuticals, Inc.
  • Endo International plc
  • Genix Pharma
  • Hetero Labs Ltd.
  • Intas Pharmaceuticals Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Mallinckrodt plc
  • Marinus Pharmaceuticals, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • MSN Laboratories
  • ORPHELIA Pharma
  • Ovid Therapeutics, Inc.
  • Sanofi S.A.
  • SGPharma Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma SA
  • Zydus Group

Table Information

Report AttributeDetails
No. of Pages197
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 453.84 Million
Forecasted Market Value ( USD ) by 2032 $ 679.12 Million
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Infantile Spasm Therapeutics Market - Global Strategic Business Report - Product Image

Infantile Spasm Therapeutics Market - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Infantile Spasm Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Infantile Spasm Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Infantile Spasm - Pipeline Insight, 2025 - Product Image

Infantile Spasm - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Infantile Spasms Therapeutics Market 2025-2029 - Product Image

Infantile Spasms Therapeutics Market 2025-2029

  • Report
  • 201 Pages
  • Global
From

About the Infantile Spasm Drug Market

Infantile Spasm (IS) is a rare neurological disorder that affects infants and young children. It is characterized by sudden, brief, and repetitive muscle contractions, usually in the form of jerking movements. Treatment for IS typically involves anticonvulsant drugs, such as vigabatrin, topiramate, and adrenocorticotropic hormone (ACTH). These drugs are used to reduce the frequency and severity of spasms, as well as to prevent further seizures. The Infantile Spasm Drug market is a subset of the Central Nervous System Drugs market. It is a small but growing market, driven by the increasing prevalence of IS and the need for effective treatments. The market is highly competitive, with a number of companies offering various drugs for the treatment of IS. Some of the major companies in the Infantile Spasm Drug market include Pfizer, Novartis, Sanofi, GlaxoSmithKline, and Merck. These companies offer a range of drugs for the treatment of IS, including vigabatrin, topiramate, and ACTH. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.